Business Wire

Finnforel to Invest EUR 45 Million in New Production Facilities and Build First Selective Breeding Centre for Rainbow Trout in Finland

9.11.2021 12:25:00 EET | Business Wire | Press release

Share

Finnish technology company Finnforel has become one of the world's leading ecological fish farms since it was founded in 2017. The company’s products are currently sold in more than a thousand grocery stores in Finland under the Saimaan Tuore brand. Finnforel achieved a significant breakthrough in November 2020, when its million-kilo production plant in Varkaus achieved maximum capacity level for premium fish farming.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211109005798/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Finnish technology company Finnforel has become one of the world's leading ecological fish farms since it was founded in 2017. With the investment programme announced today, Finnforel enters its next growth phase, as the company aims for rapid expansion in both the Finnish and global markets. (Photo: Business Wire)

With the investment programme announced today, Finnforel enters its next growth phase, as the company aims for rapid expansion in both the Finnish and global markets.

“Only 0.1 percent of all the fish in the world is produced in an ecologically sustainable way. This is a massive EUR 300 billion business that must change if we want to save our seas and lakes. I believe that Finnforel’s highly refined model, which works without antibiotics or environmental emissions, can claim a significant part of this market. Over the next decade, the mission of the Finnforel team is to bring Finnish genetics and fish farming know-how to the world. In the future, fish will be farmed where consumers are,” says Pekka Viljakainen, Chairman of the Board and one of the founders of Finnforel Oy.

Finnforel is further expanding the production capacity of its Varkaus plant from one million to three million kilos. The resulting “Finnforel Gigafactor” concept will cover the entire fish farming process, from juvenile fish to ready consumer products. Construction work on the extension, which will cost approximately EUR 25 million, will begin immediately. In December 2021, Finnforel will begin exporting its fish products to the United Kingdom, Germany and the Netherlands. At the same time, the company is entering the design phase for several similar gigafactor projects in Europe, Russia and the Middle East.

Finland’s first selective breeding centre for rainbow trout to be built in Hollola

A significant part of Finnforel’s expansion plans is to introduce to Finland industrial-scale broodstock and fry production suitable for Recirculating Aquaculture Systems. At present, most of the eggs used in fish farming in Finland are imported. Finnforel is building a EUR 12 million genetics and fry plant in Hollola that, upon completion, will have the capacity to produce eggs for six Finnforel gigafactor plants around the world.

The project, which is being implemented in close co-operation with Natural Resources Institute Finland, is also important in terms of Finland's emergency supply. Together with the Finnish institute, Finnforel will help secure the supply of fish eggs and fry, for example in crisis situations. Since the early 1990s, Natural Resources Institute Finland has carried out pioneering research in rainbow trout genetics, breeding and animal health. This project marks the first time that the results of this work are being applied and commercialised to this extent.

“According to the business model created by Finnforel, fish will be processed from eggs to consumer packaging. By securing the entire production chain, we create an easy way for consumers and retailers to buy and sell fresh and delicious fish. The consumption of fish is growing internationally, and I firmly believe that more vigilant consumers will increasingly favour organically produced alternatives that are easy and quick to prepare,” says Max Alfthan, Managing Director of Finnforel.

Significant new owners
Finnforel is financing these investments totalling EUR 45 million through a EUR 34 million share issue, EUR 4.5 million from the European Maritime and Fisheries Fund (EMFF) and EUR 6 million in loans from banks.

The share issue will make significant Finnish and international institutional investors shareholders in Finnforel. These include Ahlström Invest, Finnish Industry Investment Ltd (TESI), the European Investment Bank (European Fund for Strategic Investment), The Good Investors (Ireland/France) and other European family enterprises.

Finnforel’s press conference was held on Tuesday 9th of November from 11.00 am onwards. The recording of the press conference can be viewed here: https://www.finnforel.com/

Read more about Finnforel here: https://www.finnforel.com/
For more information: https://youtu.be/e6Q8LbLddXw

Finnforel Oy is a Recirculating Aquaculture Systems (RAS) facility and Finnish family business specialising in genetics and related technology that was founded in 2017. The company currently has pilot plants in Varkaus, Hollola and Joroinen that produce approximately one million kilos of organically farmed rainbow trout each year. The company's best-known brand is Saimaan Tuore, whose rainbow trout products are available in more than a thousand grocery stores throughout Finland.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Further information:
Pekka Viljakainen, Chairman of the Board, Finnforel Oy
bulldozer@aii.fi, tel. +358 50 1422

Max Alfthan, Managing Director, Finnforel Oy
max.ahfthan@finnforel.com, tel. +358 40 0461640

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye